Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2021-01-15 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Regulatory Filings Classification · 95% confidence The document is a formal 'Company Announcement' from Genmab regarding a regulatory milestone (FDA approval of a drug). It details the clinical context, financial implications (a $30 million milestone payment), and provides contact information for investor relations. It does not constitute a full financial report, transcript, or proxy statement. Under the provided definitions, general corporate announcements that do not fit into specific categories like M&A or dividend notices are classified as Regulatory Filings (RNS).
2021-01-15 English
6-K
Foreign Filer Report
2021-01-13 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and details a specific corporate event: Genmab receiving a USD 40 million milestone payment from AbbVie due to progress in a clinical trial (Phase 3 study of epcoritamab). This type of announcement, focusing on a specific operational or financial event (like a milestone payment or partnership update) rather than comprehensive periodic results (like 10-K or IR), is typically classified as a general corporate announcement or regulatory filing. Since it is not an Earnings Release (ER), which focuses on period results, nor a specific filing like DIRS, DIV, or CAP, it fits best under the general Regulatory Filings category (RNS) as a material, non-periodic corporate update, or potentially an Earnings Release if the milestone is material enough to be highlighted outside of the formal ER, but the structure strongly suggests a press release/company announcement. Reviewing the definitions: - ER (Earnings Release): Initial announcement of *quarterly/periodical* financial results (key highlights only). This is about a specific milestone, not the period results themselves. - CAP (Capital/Financing Update): This is a milestone payment, not fundraising or capital structure change. - RNS (Regulatory Filings): General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories. This milestone payment is a material event that must be disclosed. Given the content is a specific, material business development announcement that doesn't fit the more specific categories like ER, CAP, or DIV, RNS (Regulatory Filings) is the most appropriate classification for this type of press release/company announcement.
2021-01-13 English
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a milestone payment received by Genmab from AbbVie. It details the clinical progress of a drug (epcoritamab) and the financial impact of the milestone. While it mentions financial figures, it is a press release/announcement of a specific corporate event rather than a full financial report, earnings release, or regulatory filing. According to the 'Menu vs Meal' rule, this is a standard corporate announcement of a business development event, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2021-01-13 English
6-K
Foreign Filer Report
2021-01-05 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions in company shares by managerial employees and board members, specifically detailing the vesting of restricted stock units. This falls directly under the definition of 'Director's Dealing' (Code: DIRS), which covers reports of personal share transactions by company directors and executives.
2021-01-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.